Advertisement
Watson Pharmaceuticals
Subscribe to Watson Pharmaceuticals

The Lead

Actavis Sues FDA Regarding Delay of Generic Celebrex Approval

April 29, 2014 8:29 am | News | Comments

Actavis announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the FDA challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.

Idaho Gets $28M in Drug Price Case

August 28, 2013 1:56 pm | by The Associated Press | News | Comments

Idaho's lawsuit against several major pharmaceutical companies over allegations of inflated drug...

AstraZeneca Settles Legal Dispute with Watson

March 25, 2013 9:14 am | News | Comments

Anglo-Swedish pharmaceutical company AstraZeneca has settled a legal dispute with Watson...

Watson Acquires Uteron Pharma SA

January 23, 2013 2:53 am | News | Comments

Watson Pharmaceuticals, Inc. today announced that it has completed the acquisition of Belgium-...

View Sample

FREE Email Newsletter

Watson Announces Global Generics Management Team

November 2, 2012 6:15 am | News | Comments

Watson Pharmaceuticals, Inc. has announced the Global Generics management team, following the announcement of the completion of the acquisition of the Actavis Group .

Watson Pharma Completes Purchase of Actavis

November 1, 2012 6:15 am | News | Comments

PARSIPPANY, N.J. (AP) — Watson Pharmaceuticals Inc. completed its $5.6 billion of Swiss competitor Actavis Group Wednesday, and the company said Thursday that it expects that profit to grow at least 30 to 40 percent in 2013.  

Watson Sells Rugby Drug Business for $117M

October 30, 2012 5:48 am | News | Comments

Watson Pharmaceuticals Inc. said Monday that it has sold its over-the-counter Rugby drug business to The Harvard Drug Group LLC. for about $117 million.

Advertisement

Watson Receives Approval from European Commission for Pending Actavis Acquisition

October 8, 2012 4:10 am | News | Comments

Watson Pharmaceuticals, Inc. has announced that the European Commission (EC) has approved the company's pending acquisition of the privately held Actavis Group.

Watson's Generic Lidoderm Receives FDA Approval

August 24, 2012 3:57 am | News | Comments

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the FDA on its Abbreviated New Drug Application (ANDA) for lidocaine topical patch 5%, the generic equivalent to Endo's Lidoderm.

Watson's Generic Version of Pulmicort RESPULES Receives FDA Approval

August 1, 2012 4:38 am | News | Comments

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension 0.25mg/2mL and 0.5mg/2mL Unit-dose ampules, the generic equivalent to AstraZeneca's Pulmicort RESPULES.

Watson Confirms Xopenox HFA Patent Challenge

July 30, 2012 4:12 am | News | Comments

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Levalbuterol Tartrate Inhalation Aerosol,0.045 mg/actuation. Watson's ANDA product is a generic version of Sunovion Pharmaceuticals, Inc.'s Xopenox HFA which is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.  

Watson's Generic Version of Plan B One-Step Receives FDA Approval

July 13, 2012 4:31 am | News | Comments

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Next ChoiceT ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step.

Advertisement

Watson: Court Agrees Sanctura XR Patents Not Valid

June 19, 2012 4:19 am | News | Comments

PARSIPPANY, N.J. (AP) — Watson Pharmaceuticals Inc. said Monday that a federal appeals court agreed with its argument that four of the patents on the overactive-bladder treatment Sanctura XR are not valid.  

Watson Announces Lidoderm Patent Challenge Settlement

May 29, 2012 4:01 am | News | Comments

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an agreement with Endo Pharmaceuticals Inc. and Teikoku Seiyaku Co., Ltd to settle all outstanding patent litigation related to Watson's generic version of Lidoderm.

Watson Confirms Testim Patent Challenge

May 25, 2012 4:32 am | News | Comments

Watson Pharmaceuticals, Inc. has confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals, Inc.'s Testim 1%.  

Auxilium Pharmaceuticals and FCB File Lawsuit Against Watson for Infringement of Testim Patents

May 24, 2012 4:02 am | News | Comments

Auxilium Pharmaceuticals, Inc. and FCB I LLC announced today that they filed a lawsuit against Watson Laboratories, Inc. (NV); Watson Pharmaceuticals, Inc.; and Watson Pharma, Inc. for infringement of FCB's ten patents listed in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book") as covering Testim 1% testosterone gel. 

Watson Confirms Lialda Patent Challenge

May 10, 2012 4:05 am | News | Comments

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Mesalamine Delayed-release Tablets, 1.2g.  

Advertisement

M & A Activity Heats Up In April

May 1, 2012 5:35 am | News | Comments

  April proved to be a big month for M&A activity as companies announced more than $29 billion in agreed upon transactions during the month, the bulk of which occurred during the final week.

Watson Announces Restructuring of Senior Leadership to Support Expanded Global Businesses

April 27, 2012 6:58 am | News | Comments

Watson Pharmaceuticals, Inc. today announced that it has refined and expanded the responsibilities of its senior executive team, in recognition of the company's continued global expansion, particularly following the announcement of Watson's intention to acquire Actavis.

Watson Launches Generic FORTAMET

April 20, 2012 4:07 am | News | Comments

Watson Pharmaceuticals, Inc. today announced that it has launched an authorized generic version of FORTAMET (metformin hydrochloride extended-release tablets) as part of an agreement with Shionogi, Inc.  

Watson Confirms Glumetza Patent Challenge

April 19, 2012 7:20 am | News | Comments

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Metformin Hydrochloride Extended-release Tablets USP, 1000 mg. Watson's Metformin Hydrochloride Extended-release Tablets are a generic version of Depomed, Inc.'s Glumetza.

Watson Confirms Favorable Ruling in Generic Sanctura XR Patent Suit

April 4, 2012 4:00 am | News | Comments

Watson Pharmaceuticals, Inc. today confirmed that the United States District Court for the District of Delaware has ruled that the asserted claims of United States Patent Nos. 7,410,978 (the '978 Patent), 7,759,359 (the '359 Patent), 7,781,448 (the '448 Patent), 7,781,449 (the '449 Patent) and 7,763,635 (the '635 Patent) for Sanctura XR (trospium chloride extended-release capsules) are invalid.

Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%

February 27, 2012 3:01 am | News | Comments

Watson Pharmaceuticals, Inc. and Columbia Laboratories, Inc. today confirmed that, as expected, Watson has received a complete response letter from the FDA for its New Drug Application (NDA 22-139) for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy.

Columbia Laboratories Transfers NDA for Progesterone Vaginal Gel 8% to Watson Pharmaceuticals

February 13, 2012 3:02 am | News | Comments

Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced that Columbia has transferred the new drug application for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy (NDA 22-139) to Watson.

Watson Sets Aside $6B to Buy Brand-Name Drug Assets

February 9, 2012 5:00 am | by Matthew Dennis | News | Comments

Watson Pharmaceuticals CEO Paul Bisaro said the company has around $6 billion to spend on acquisitions as it looks to buy brand-name drug assets, signaling a move away from the company's focus on generic medicines, Bloomberg reported Thursday.

Watson and J & J Settle Ortho Tri-Cyclen Dispute

February 8, 2012 7:17 am | by The Associated Press | News | Comments

Watson Pharmaceuticals Inc. said Wednesday it settled a patent lawsuit brought by a unit of Johnson & Johnson over a generic version of the birth control drug Ortho Tri-Cyclen Lo.

Watson CEO: Pfizer’s Plan against Copies May Not Be ‘Worth It’

January 25, 2012 4:51 am | by Bloomberg via NewsPoints Desk | News | Comments

Watson CEO Paul Bisaro said that Pfizer’s strategy to keep its market share of Lipitor may boost revenue without aiding profit, Bloomberg reported.  

Watson 2011 Earnings Jump after Launch of Generic Drugs

January 24, 2012 5:08 am | by the Associated Press | News | Comments

Generic drugmaker Watson Pharmaceuticals Inc. said Tuesday its 2011 adjusted earnings per share increased about 39 percent compared to 2010, as the launch of some key products boosted revenue.

Watson Acquires Strides Arcolab Generics Unit for $393M

January 24, 2012 4:07 am | by Matthew Dennis | News | Comments

Watson Pharmaceuticals said Tuesday it has bought Strides Arcolab's generics unit Ascent Pharmahealth for 375 million Australian dollars ($393 million) in cash.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading